ClinicalTrials.gg
RecruitingNCT05537662XANADOUpdated Jul 12, 2024

External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes (XANADO)

An interventional study of Standard of care neuromodulation therapy (SCS or DRG) in Chronic Pain, sponsored by Abbott Medical Devices. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-12.

Sponsored by Abbott Medical Devices (part of Abbott) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Chronic Pain by Abbott — 2 open to participants now, 2 under way, none of them phase 3. Chronic Pain · Abbott.

Planned enrollment
7th of 12
30 · median 43
Started
2023
the only one that year
No phase
12 of 19
1 open now
Registered
17th of 19
by date

Among the 19 studies in Chronic Pain by Abbott, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 12 with no phase, and was the 17th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

2 of the 19 studies in Chronic Pain by Abbott are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Chronic Pain by Abbott, or all of them as a file.
02

Study summary

This is a prospective, longitudinal, single-center, non-randomized, open-label, post-market clinical feasibility study to assess the efficacy of neuromodulation therapies (SCS and DRG) for chronic pain patients with diabetes and investigate whether physical and physiological data collected from diabetic and pre-diabetic chronic pain patients is predictive of subjective patient-reported outcomes (PROs) and of adjustments in patient care. These assessments will be made prior to, during, and after the trial of the SCS or DRG system. The study will be carried out in the United States at a single site.

03

Conditions studied

  • Chronic Pain

Browse trials for

Keywords

  • ABT-CIP-10458
  • Chronic Pain
  • Neuromodulation System
  • SCS
  • Diabetic Pain
  • DRG
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must provide written prior to any clinical investigation-related procedure.
  2. Subject is at least 18 years of age or older at the time of enrollment.
  3. Subject's scheduled trial duration for the Abbott neuromodulation system is at least 7 days.
  4. Subject is scheduled to undergo trial of an Abbott neuromodulation system for chronic intractable back and/or leg pain at least 7 days after enrollment and commencement of the baseline data collection period.
  5. Subject agrees to take an screening test prior to study enrollment and has a confirmed HbA1C level ≥ 5.7%.
  6. Subject has a baseline (with no stimulation) pain NRS of ≥ 6.
  7. Subject is willing to cooperate with the study requirements including completion of all office visits.
  8. Subject agrees to wear the wearable sensing devices (Fitbit® and Freestyle Libre).
  9. Subject agrees to answer questionnaires regularly for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Subject is enrolled, or intends to participate, in a competing or confounding clinical study, as determined by Abbott.
  2. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period.
  3. Subject is part of a vulnerable population.
  4. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results.
  5. Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease, post-herpetic neuralgia.
  6. Subject has, or is scheduled to receive, implantation of another neuromodulation system (e.g. DRG or SCS system or intrathecal pump) to address their chronic pain.
  7. Subject has already participated in a SCS trial period before enrolling in the study.
  8. Subject engages in a profession or other activity that could be damaging to the wearable sensors, as determined by the investigator.
  9. Subject has a physical condition that makes it difficult to wear the wearable sensors, as determined by the investigator.
  10. Subject has tremors (e.g. Parkinson's disease or Familial tremors).
  11. Subject has sleep/wake schedule that would present a challenge in completing all clinical site visits or in use of the wearable devices and engagement in the surveys via the mobile device.
  12. Subject is bedridden.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Subjects using Neuromodulation Therapy (SCS or DRG)

    Patients will trial standard of care neuromodulation therapy (SCS or DRG), and if successful will proceed to a permanent implant.

    Device: Standard of care neuromodulation therapy (SCS or DRG)

Interventions

  • DeviceStandard of care neuromodulation therapy (SCS or DRG)

    Standard SCS or DRG therapy

06

What researchers measure

Primary outcomes

  1. The mean change in pain scores measured by the Numerical Rating Scale (NRS) at baseline and follow up at 3 months

    Change in pain scores measured by the NRS at baseline and follow up study visits at 3 months.

    Time frame: At 3 month

  2. The mean change in pain scores measured by the Numerical Rating Scale (NRS) at baseline and follow up at 6 months

    Change in pain scores measured by the NRS at baseline and follow up study visits at 6 months.

    Time frame: At 6 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jan 2025, 19 months after the start.

Of 83 industry-sponsored interventional studies with no phase under Chronic Pain, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's planned 19 months is close to that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2022
First posted
Sep 13, 2022
StartActual
Jun 6, 2023
Primary completionEst.
Jan 2025
CompletionEst.
Apr 2025
Last update
Jul 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05537662
Responsible party
Sponsor
First posted
Sep 13, 2022
Start date
Jun 6, 2023
Primary completion
Jan 2025 (estimated)
Completion
Apr 2025 (estimated)
Last update
Jul 12, 2024

Study contacts

Bram Blomme
Contact
bram.blomme@abbott.com
+32 (0)2 774 68 50

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion